Skip to Main Content

Paper Details

Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Br J Haematol
9
2021
Author NameAffiliation
Suzanne Kamel-ReidToronto General Hospital, University Health Network, University of Toronto
  • 1 - 1

Datasets

Release 1.2